Articles

Human genomics for the masses

Roche and IBM collaborate on nanopore-based DNA sequencing technology with eyes toward advancing personalized healthcare
Written byJeffrey Bouley
| 5 min read

BRANFORD, Conn.—IBM launched itself into the sequencing market in life sciences in a big way in late 2009 with the announcement of its DNA Transistor technology and the prediction that it might not just usher in the age of the $1,000 genome, but perhaps bring that price down to three-figure levels in the forseeable future. Now the Armonk, N.Y.-based information technology powerhouse is being joined in that effort by Swiss-headquartered pharmaceutical and diagnostics giant Roche and its Connecticut-based sequencing subsidiary, 454 Life Sciences.

Under the agreement, Roche and IBM will develop a nanopore-based sequencer designed to directly read and decode human DNA quickly and efficiently. In advancing IBM's promising but fledgling DNA Transistor technology, the collaboration will take advantage of IBM's leadership in microelectronics, information technology and computational biology and Roche's expertise in medical diagnostics and genome sequencing.

The novel technology that was developed by IBM Research has been called a "DNA bar code reader" by some market watchers, because it offers single-molecule sequencing by decoding molecules of DNA as they are threaded through a nanometer-sized pore in a silicon chip.

It was a logical fit for Roche and IBM to come together in refining the technology, because Roche and its 454 subsidiary offer the longest read lengths right now with their next-generation sequencing platforms, notes Dr. Ulrich Schwoerer, head of global marketing for 454 Life Sciences Corp. "We also have a lot of experience with next-gen technology and taking it to market, and we are the world's largest biotech and diagnostics company."

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.